NASDAQ:CTMX - CytomX Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $24.51 -0.12 (-0.49 %) (As of 07/20/2018 04:52 AM ET)Previous Close$24.63Today's Range$23.93 - $25.0152-Week Range$13.09 - $35.00Volume405,600 shsAverage Volume406,847 shsMarket Capitalization$935.37 millionP/E Ratio-21.14Dividend YieldN/ABeta0.92 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Receive CTMX News and Ratings via Email Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:CTMX CUSIPN/A Webwww.cytomx.com Phone650-515-3185 Debt Debt-to-Equity RatioN/A Current Ratio5.27 Quick Ratio5.27 Price-To-Earnings Trailing P/E Ratio-21.14 Forward P/E Ratio-15.42 P/E GrowthN/A Sales & Book Value Annual Sales$71.62 million Price / Sales13.33 Cash FlowN/A Price / CashN/A Book Value$1.82 per share Price / Book13.47 Profitability EPS (Most Recent Fiscal Year)($1.16) Net Income$-43,090,000.00 Net Margins-67.88% Return on Equity-92.68% Return on Assets-13.31% Miscellaneous Employees93 Outstanding Shares38,960,000Market Cap$935.37 CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions What is CytomX Therapeutics' stock symbol? CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX." How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics Inc (NASDAQ:CTMX) posted its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.17. The biotechnology company had revenue of $14.18 million for the quarter, compared to the consensus estimate of $19.77 million. CytomX Therapeutics had a negative return on equity of 92.68% and a negative net margin of 67.88%. View CytomX Therapeutics' Earnings History. When is CytomX Therapeutics' next earnings date? CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for CytomX Therapeutics. What price target have analysts set for CTMX? 10 equities research analysts have issued twelve-month price objectives for CytomX Therapeutics' shares. Their predictions range from $37.00 to $44.00. On average, they anticipate CytomX Therapeutics' share price to reach $39.8571 in the next twelve months. This suggests a possible upside of 62.6% from the stock's current price. View Analyst Ratings for CytomX Therapeutics. What is the consensus analysts' recommendation for CytomX Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of CytomX Therapeutics' key competitors? Some companies that are related to CytomX Therapeutics include Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), The Medicines (MDCO), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Intercept Pharmaceuticals (ICPT), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Evotec (EVTCY), Emergent Biosolutions (EBS), Portola Pharmaceuticals (PTLA) and Spectrum Pharmaceuticals (SPPI). Who are CytomX Therapeutics' key executives? CytomX Therapeutics' management team includes the folowing people: Dr. Sean A. McCarthy, Pres, CEO & Director (Age 51)Mr. Debanjan Ray, CFO & Head of Corp. Devel. (Age 40)Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 57)Dr. W. Michael Kavanaugh, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 62)Ms. Danielle Olander, Sr. VP of Talent & Admin. Operations Has CytomX Therapeutics been receiving favorable news coverage? Press coverage about CTMX stock has trended somewhat positive on Friday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CytomX Therapeutics earned a news impact score of 0.11 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 49.67 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Foundry Partners LLC (0.10%), Bank of Montreal Can (0.09%), Essex Investment Management Co. LLC (0.06%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Rachel Humphrey, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy, Timothy M Shannon and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics. Which major investors are selling CytomX Therapeutics stock? CTMX stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Foundry Partners LLC. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck, Rachel Humphrey, Robert I Tepper, Sean A Mccarthy and William Michael Kavanaugh. View Insider Buying and Selling for CytomX Therapeutics. Which major investors are buying CytomX Therapeutics stock? CTMX stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for CytomX Therapeutics. How do I buy shares of CytomX Therapeutics? Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CytomX Therapeutics' stock price today? One share of CTMX stock can currently be purchased for approximately $24.51. How big of a company is CytomX Therapeutics? CytomX Therapeutics has a market capitalization of $935.37 million and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe. How can I contact CytomX Therapeutics? CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected] MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 204 (Vote Outperform)Underperform Votes: 144 (Vote Underperform)Total Votes: 348MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?